FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...
In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...
Scientific publicationFormycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of ...
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard) (“Formycon” or “the Company”) today provided an update on key developments across various biosimilar projects and invites ...
Formycon anticipates a non-cash impairment in the range of high double-digit to low triple-digit millions due to higher-than-expected price discounts for biosimilars as it prepares for the U.S. market ...
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing ...
The first month of 2025 was an interesting one, with inflation rising faster than expected, giving another motivation for the ...
Zacks.com on MSN3d
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected ...
Formycon’s shares edged up 2.4% to 30.60 euros as it revealed it is presenting an overview of the comparative data of the ...
UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback